StocksMedium•6 October 2026•
1 min read
Pelthos Therapeutics Expands ZELSUVMI Coverage to 127 Million Lives
Key Facts
1Pelthos Therapeutics signed an agreement with a major Pharmacy Benefit Manager to provide access to ZELSUVMI for an additional 24 million covered lives.
2Total commercial coverage for ZELSUVMI increased to 127 million covered lives following the new agreements.
Pelthos Therapeutics signed an agreement with a major Pharmacy Benefit Manager to provide access to ZELSUVMI for an additional 24 million covered lives. Reuters reported that total commercial coverage for the drug increased to 127 million covered lives following the new agreements.
PTHS closed at $20.5 on October 5, 2026, after reaching a day high of $21.74. This commercial expansion aims to increase market penetration for the topical gel in the U.S. market, as the contracted Pharmacy Benefit Manager serves approximately one in three Americans.